碩士 / 國立臺灣海洋大學 / 食品科學系 / 101 / Pneumonia is one of the leading causes of morbidity and mortality. Gentamicin (GM) is an aminoglycoside antibiotic commonly used for treating pneumonia disease. However, the use of GM is limited by a relatively short half-life and the dose-related adverse effects as ototoxicity and nephrotoxity is reflected in its low therapeutic index. In this investigation, we devel¬oped a controlled-release GM formulation using chitosan/fucoidan nanoparticles (CS/F NPs). The results suggest that nanoparticles composed of CS and F were successfully prepared based on their electrostatic interaction. The mean particle size of CS/F NP was around 246.1 nm as the weight ratio of CS to F was 5:1 and GM loaded CS/F NPs (GM/CS/F NPs) was around 271.1 nm in simulated lung fluid. The GM can be highly encapsulated and sustained release from CS/F NPs for up to 72 hrs. The MTT cell viability assay revealed an absence of overt toxicity to A549 or Raw 264.7 cells following exposure to the formulations containing < 0.8 mg NP/ml for up to 24 hrs. Inflammation and intracellular ROS assay revealed that CS/F NPs are suitable biomaterials without inducing inflammatory or oxidative reactions. GM-loaded CS/F NPs are effective in resisting Klebsiella pneumonia with low minimum inhibitory concentrations (MICs) at 1.95 μg/mL. Briefly, all the results mentioned above suggest that the CS/F NPs developed in this study are a promising carrier for pulmonary delivery of GM against pneumonia.
| Identifer | oai:union.ndltd.org:TW/101NTOU5253062 |
| Date | January 2013 |
| Creators | Rou-ying Li, 李柔瑩 |
| Contributors | Yi-Cheng Huang, 黃意真 |
| Source Sets | National Digital Library of Theses and Dissertations in Taiwan |
| Language | zh-TW |
| Detected Language | English |
| Type | 學位論文 ; thesis |
| Format | 111 |
Page generated in 0.002 seconds